In line with this study, it was recently reported that IMGN632 exerted in vivo a pronounced efficacy against patient-derived xenografts (PDXs) derived from a wide range of ALL subtypes, expressing various levels of CD123 [131]. This evidence concerns the gene IL3RA and acute lymphoblastic leukemia.